YL413

YL413 is a novel dual-payload antibody-drug conjugate (ADC) targeting Human Epidermal Growth Factor Receptor 2 (HER2), developed by MediLink Therapeutics. It is engineered with a trastuzumab-based antibody conjugated to two distinct payloads with different mechanisms of action: a topoisomerase I inhibitor and a microtubule inhibitor. This dual-payload strategy is designed to mitigate resistance associated with single-agent therapies and overcome tumor heterogeneity, specifically targeting mechanisms that lead to resistance against existing HER2 ADCs like Enhertu (trastuzumab deruxtecan). Preclinical studies have demonstrated that YL413 exhibits potent anti-tumor activity in HER2-positive cell lines and superior efficacy in cell-derived xenograft (CDX) models, including those resistant to topoisomerase I inhibitors.